Építés alatt – nem éles oldal
Belépés

What researchers published on Gaucher-kór

1567 papers, newest first.

Showing 20 of 32

  • Vizsgálati eredményIncreased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulation.Journal of internal medicine
  • Randomizált vizsgálatA 6-month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications.Journal of inherited metabolic disease
  • Vizsgálati eredményQualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP).Advances in therapy
  • Randomizált vizsgálatPhase 1 Healthy Volunteer Study of AL01211, an Oral, Non-brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease.Clinical pharmacology in drug development
  • Vizsgálati eredményRadiographic Cortical Thickness Index Predicts Fragility Fracture in Gaucher Disease.Radiology
  • Randomizált vizsgálatClinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.American journal of hematology
  • Vizsgálati eredményPredicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia.Scientific reports
  • Vizsgálati eredményOpen-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.Blood cells, molecules & diseases
  • Vizsgálati eredményImpact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.Molecular genetics and metabolism
  • Randomizált vizsgálatLong-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.Orphanet journal of rare diseases
  • Vizsgálati eredményOutcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.American journal of hematology
  • Vizsgálati eredményIntra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.Clinical pharmacokinetics
  • Randomizált vizsgálatOnce- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.Molecular genetics and metabolism
  • Vizsgálati eredményA multicenter, open-label, phase III study of Abcertin in Gaucher disease.Medicine
  • Randomizált vizsgálatImmunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story.PloS one
  • Vizsgálati eredményReductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.Molecular genetics and metabolism
  • Randomizált vizsgálatOutcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.American journal of hematology
  • Vizsgálati eredményTransformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.American journal of hematology
  • Vizsgálati eredményAssessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • Randomizált vizsgálatEliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.Blood